EAY191-A3 (RAS-Mutant Cancers) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if a study drug called binimetinib is a safe and effective option for cancers that harbor certain genetic mutations (RAS/RAF/MEK). We want to know how well it works on its own for some cancers, and how it works in combination with another study drug called palbociclib for other cancers.
Cancers with RAS/RAF/MEK Mutations
Who Can Participate in the Study?
Adults ages 18+ who are diagnosed with a form of cancer with tumor(s) that have one of the following mutations: RAS, KRAS, NRAS, HRAS, non-BRAF V600E, or rare RAF fusions.
People diagnosed with the following types of cancer will not be eligible to join: non-small cell lung cancer, colorectal cancer, and melanoma.
For more information about who can join this study, contact the study team at nick.jeffries@duke.edu.
What is Involved?
This study involves 4 different participation groups. The group(s) in which you are able to participate will depend on what type of cancer you have and its mutations.
If you choose to participate and are in Group 1, you will get a random assignment (like a coin flip) to receive either binimetinib alone or in combination with palbociclib. You will get these drugs as pills you take by mouth. Binimetinib will be taken two times a day for 28 days and palbociclib will be taken once a day for 28 days.
If you choose to participate and are in Group 2, Group 3, or Group 4, you will get binimetinib and palbociclib as pills you take by mouth with binimetinib taken two times a day for 28 days and palbociclib taken once a day for 28 days.
Study Details
